
Widely used diabetes and obesity drugs don’t increase the risk of breast cancer, a new study indicates. The drugs — called glucagon like peptide-1 receptor agonists or GLP-1 RAs for short — are effective in treating type 2 diabetes and obesity and in reducing heart disease. But some previous studies have suggested a possible link… read on > read on >